摘要： 目的 探讨五酯胶囊增加他克莫司血药浓度在特发性膜性肾病中的疗效和安全性。方法 收集中国医科大学附属第一医院肾内科收治的特发性膜性肾病患者58例，分为单用他克莫司组（单药治疗组，n=27）和他克莫司联合五酯胶囊治疗组（联合治疗组，n=31），比较2组患者他克莫司血药浓度达标时间、治疗有效性和安全性。结果 与单药治疗组比较，联合治疗组血药浓度达标剂量更低（P=0.007），血药浓度达标时间更短（P=0.007），3个月的肾脏缓解率更高（P=0.034），2组不良反应发生率无明显差别（P > 0.05）。结论 治疗特发性膜性肾病中联合应用五酯胶囊能够减少他克莫司血药浓度达标剂量和达标时间，可望更快诱导肾脏缓解且不增加药物不良反应。

五酯胶囊增加他克莫司血药浓度治疗特发性膜性肾病的效果

张俊晓, 郑建楠, 杨伟光, 范秋灵, 姚丽, 刘林林

中国医科大学附属第一医院肾内科, 沈阳 110001

收稿日期:2019-11-20出版日期:2020-08-30发布日期:2020-08-04
通讯作者:刘林林E-mail:catherine-ll@126.com
作者简介:张俊晓(1995-),女,硕士研究生.
基金资助:国家自然科学基金（81970617，81500525）；辽宁省自然科学基金（2019-MS-367）


关键词: 五酯胶囊, 他克莫司, 特发性膜性肾病
Abstract: Objective To explore the efficacy and safety of using Wuzhi capsule to increase the blood concentration of tacrolimus in the treatment of idiopathic membranous nephropathy. Methods A total of 58 patients with idiopathic membranous nephropathy admitted to the First Hospital,China Medical University,were enrolled in the study and received either tacrolimus monotherapy (n=27) or combined therapy of tacrolimus and Wuzhi capsule (n=31). The time to reach the standard blood concentration of tacrolimus and treatment efficacy and safety were compared between the two groups. Results Compared with the monotherapy group,the combined therapy group had lower target doses (P=0.007),a shorter time (P=0.007) to the target blood concentration of tacrolimus,and a higher 3-month renal remission rate (P=0.034). There was no significant difference between the incidence of adverse effects observed in the two groups (P > 0.05). Conclusion The combination of Wuzhi capsule and tacrolimus in the treatment of idiopathic membranous nephropathy can reduce the dose and time required to reach the standard blood concentration of tacrolimus,and may induce faster renal remission without increasing adverse effects.
Key words: Wuzhi capsule, tacrolimus, idiopathic membranous nephropathy
PDF全文下载地址:

https://journal.cmu.edu.cn/CN/article/downloadArticleFile.do?attachType=PDF&id=2573